kazia therapeutics ltd adr美股招股说明书(2025-06-10版)

Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectusdated December 2, 2024 (the “Prospectus”), which forms a part of our Registration Statement on Form F-1(Registration No. 333-279773), with the information contained in our current report on Form 6-K, furnished to theSecurities and Exchange Commission on June 10, 2025 (the “June 10, 2025 Form 6-K”). Accordingly, we haveattached the June 10, 2025 Form 6-K to this prospectus supplement. This prospectus supplement updates and supplements the information in the Prospectus and is not complete without,and may not be delivered or utilized except in combination with, the Prospectus, including any amendments orsupplements thereto. This prospectus supplement should be read in conjunction with the Prospectus and if there isany inconsistency between the information in the Prospectus and this prospectus supplement, you should rely on theinformation in this prospectus supplement. The ADSs are listed on The Nasdaq Capital Market (“Nasdaq”) under the symbol “KZIA.” On June 9, 2025, the lastreported sale price of the ADSs on Nasdaq was $5.30 per ADS. Investing in our securities involves a high degree of risk. See “Risk Factors” beginning onpage 9 of the Prospectus and the “Risk Factors” in “Item 3. Key Information-D. RiskFactors” of our most recent Annual Report on Form 20-F, which is incorporated byreference in the Prospectus, as well as in any other recently filed reports and, if any, in anyapplicable prospectus supplement. Neither the Securities and Exchange Commission nor any state securities commission has approved ordisapproved of these securities or passed upon the adequacy or accuracy of the Prospectus or this prospectussupplement. Any representation to the contrary is a criminal offense. UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUERPURSUANT TO RULE 13a-16 OR 15d-16UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2025 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000(Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F☒Form 40-F☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule101(b)(1):☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule101(b)(7):☐ INFORMATION CONTAINED IN THIS FORM 6-K REPORT On June 9, 2025, Kazia Therapeutics Limited (the “Company”) reported its unaudited half-year results for the sixmonths ended December 31, 2024, a copy of which is attached to this Form 6-K as Exhibit 99.1. The Company hereby incorporates by reference the information contained herein into the Company’s registrationstatements on Form F-3 (File No. 333-276091 and 333-281937). EXHIBIT LIST SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to besigned on its behalf by the undersigned, thereunto duly authorized. Kazia Therapeutics Limited(Registrant) /s/ John FriendJohn FriendChief Executive OfficerDate: 10 June 2025 Exhibit 99.1 Half Yearly Report - 31 December 2024 Kazia Therapeutics LimitedDirectors’ report31 December 2024 The directors present their report, together with the financial statements, on the Consolidated entity (referred tohereafter as the ‘Consolidated entity’) consisting of Kazia Therapeutics Limited (referred to hereafter as the‘Consolidated entity’ or ‘parent entity’) and the entities it controlled at the end of, or during, the half-year ended31 December 2024. Directors The following persons were directors of Kazia Therapeutics Limited during the whole of the financial year and up tothe date of this report, unless otherwise stated: Iain RossBryce CarmineSteven CoffeyEbru DavidsonDr John FriendRobert Apple Principal activities During the financial year the principal continuing activity of the Consolidated entity consisted of pharmaceuticalresearch and development with a view to commercialising the results of our research through license transactions orother means. Review of operations The loss for the Consolidated entity after providing for income tax amounted to $10,453,811 (31 December 2023:$8,823,513). The attached financial statements detail the performance and financial position of the Consolidated entity for thehalf-year ended 31 December 2024. Cash resources At 31 December 2024, the Consolidated entity had total funds of $3,064,308 comprising cash in hand and at bank. Going concern The half-year financial report has been prepared on a going concern basis, which assumes continuity of normalactivities and the realisat